Tevogen Bio secures $6 million in Series C preferred stock

WARREN, NJ, Aug. 22, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics for oncology, neurology and virology, has entered into a…